Takeda-Abbott Deal To Split TAP Followed Several Failed Attempts
This article was originally published in PharmAsia News
The deal with Abbott Laboratories to end their TAP Pharmaceutical Products partnership leaves Takeda Pharmaceuticals with a cash trove intact to buy a bigger firm. Abbott, a U.S. firm, came around to the split after it failed to sell its diagnostic machine arm to General Electric just over a year ago. Takeda was under pressure to make the deal because two of its major drugs, Prevacid (lansoprazole) for ulcers and Actos (pioglitazone hydrochloride) for diabetes, are due to lose their patent protection soon. Takeda plans to garner increased proficiency by merging TAP's sales and development arms with Takeda's other U.S. subsidiaries. (Click here for more - a subscription may be required
You may also be interested in...
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.